Krebs
Studienlage · Detail Systematic Review and Meta-Analysis · Krebs · 2024

Does medicinal cannabis affect depression, anxiety, and stress in people with cancer? A systematic review and meta-analysis of intervention studies.

Kein Nutzen nachgewiesen GRADE Hoch 12 Zitate
Stichprobek = 15 Studien
n = 1.898 Pat.
Dauerunklar
KontrolleVerschiedene Kontrollen
EndpunktInzidenz/Schwere von Angst…
Verblindungunklar
DesignSystematic Review and Meta-Analysis
Kernaussage

Medizinisches Cannabis zeigte keine klinisch signifikanten Effekte auf Depression, Angst und Stress bei Krebspatienten; höhere THC-Dosen erhöhten sogar das Angst-Risiko, während nur Appetit verbessert wurde.

Zusammenfassung

Systematische Übersicht und Meta-Analyse (k=15 Studien, davon 11 RCTs; N=1.898 Krebspatient:innen): Medizinisches Cannabis (THC, CBD, Pflanzenextrakte) zeigte keinen klinisch relevanten Effekt auf Depression, Angst oder Stress als primäre Endpunkte. Höheres synthetisches THC erhöhte das Angstrisiko vs. Niedrigdosis (OR=2,0; 95%-KI: 1,4–2,9; p<0,001; Konfidenz: sehr niedrig). Sekundär verbesserte Medizinalcannabis den Appetit (OR=12,3; 95%-KI: 3,5–45,5; p<0,001; Konfidenz: moderat). Schlussfolgerung: Unzureichende Evidenz für Wirksamkeit bei psychiatrischen Symptomen; gut konzipierte Studien erforderlich.

P
PopulationErwachsene mit aktiver Krebserkrankung (100% ≥18 Jahre), gepoolt N=1898
I
InterventionMedizinisches Cannabis (THC synthetisch/pflanzlich, CBD ± THC, Ganzpflanzenextrakte, verschiedene Dosierungen und Applikationen)
C
KontrolleVerschiedene Kontrollen (Placebo oder aktive Kontrolle)
O
OutcomeKeine klinisch bedeutsamen Effekte auf Depressionen, Angst oder Stress; höhere synthetische THC-Dosis erhöht Angstereignisse (OR 2,0; 95%-KI 1,4–2,9; p<0,001); verbesserter Appetit (OR 12,3; 95%-KI 3,5–45,5; p<0,001); GRADE-Konfidenz überwiegend sehr niedrig bis moderat
Vertrauen in die Evidenz
Hoch

Höchste von vier GRADE-Stufen, die Effektschätzung ist sehr verlässlich.

Qualitätsprofil
Größe
Verblindung
Effektstärke Kein Nutzen
Zitate / Jahr
Autoren
Crichton M, Dissanayaka T, Marx W, Gamage E, Travica N, Bowers A, Isenring E, Yates P, Marshall S
DOI 10.1016/j.maturitas.2024.107941
Design: Systematic Review and Meta-Analysis
Teilen
Abstract
Medicinal cannabis might have a role in supporting the mental health of people with cancer. This systematic review and meta-analysis examined the efficacy and safety of medicinal cannabis, compared with any control, as an intervention for depression, anxiety, and stress symptoms in people living with cancer. A secondary aim was to examine the effect of low versus high Δ-tetrahydrocannabinol (THC) dose on these outcomes. Five databases were systematically searched, and complemented with a snowball search from inception to May 2023, for any type of interventional study that included humans of any age with any cancer type. Primary outcomes were incidence and severity of depression, anxiety, and stress symptoms. Secondary outcomes were mood, cognition, quality of life, appetite, nutrition status, gastrointestinal symptoms, and adverse events. Data were pooled using Review Manager. Evidence was appraised using Cochrane risk of bias tools. Confidence in the estimated effect of pooled outcomes was assessed using GRADE. Fifteen studies (n=11 randomized trials, n=4 non-randomized trials) of 18 interventions (N=1898 total participants; 100% ≥18 years of age) were included. Ten studies examined THC (70% synthetic), two synthetic cannabidiol with or without THC, and six whole-plant extracts. No clinically significant effects of medicinal cannabis were found on primary outcomes. The likelihood of anxiety events increased with higher-dose synthetic THC compared with a lower dose (OR: 2.0; 95% CI: 1.4, 2.9; p<0.001; Confidence: very low). Medicinal cannabis increased the likelihood of improved appetite (OR: 12.3; 95% CI: 3.5, 45.5; p<0.001; n=3 interventions; Confidence: moderate) and reduced severity of appetite loss (SMD: -0.4; 95% CI: -0.8, -0.1; p=0.009; Confidence: very low). There was very low confidence that higher doses of synthetic THC increased the likelihood of any adverse event (OR: 0.5; 95% CI: 0.3, 0.7; p<0.001). Medicinal cannabis had no effect on emotional functioning, mood changes, confusion, disorientation, quality of life, and gastrointestinal symptoms. Confidence in findings was limited by some studies having high or unclear risk of bias and imprecise pooled estimates. There was insufficient evidence to determine the efficacy and safety of medicinal cannabis as a therapeutic intervention for depression, anxiety, or stress in people with active cancer.

„Was dem Handeln im Weg steht, wird zum Weg.“ — Marc Aurel